The therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.
Daniel H. Foley, MD
Articles by Daniel H. Foley, MD
The therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.